The half-year results for medmix AG (VTX:MEDX) were released last week, making it a good time to revisit its performance. Revenues came in 7.2% below expectations, at CHF214m. Statutory earnings per share were relatively better off, with a per-share profit of CHF0.15 being roughly in line with analyst estimates. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.
Following last week's earnings report, medmix's three analysts are forecasting 2026 revenues to be CHF440.2m, approximately in line with the last 12 months. Statutory earnings per share are predicted to jump 10,770% to CHF0.27. Before this earnings report, the analysts had been forecasting revenues of CHF446.9m and earnings per share (EPS) of CHF0.34 in 2026. So there's definitely been a decline in sentiment after the latest results, noting the large cut to new EPS forecasts.
See our latest analysis for medmix
It might be a surprise to learn that the consensus price target was broadly unchanged at CHF15.80, with the analysts clearly implying that the forecast decline in earnings is not expected to have much of an impact on valuation. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. The most optimistic medmix analyst has a price target of CHF16.00 per share, while the most pessimistic values it at CHF15.40. Still, with such a tight range of estimates, it suggeststhe analysts have a pretty good idea of what they think the company is worth.
Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. It's clear from the latest estimates that medmix's rate of growth is expected to accelerate meaningfully, with the forecast 1.5% annualised revenue growth to the end of 2026 noticeably faster than its historical growth of 0.1% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 7.0% per year. It seems obvious that, while the future growth outlook is brighter than the recent past, medmix is expected to grow slower than the wider industry.
The Bottom Line
The most important thing to take away is that the analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have forecasts for medmix going out to 2028, and you can see them free on our platform here.
Even so, be aware that medmix is showing 1 warning sign in our investment analysis , you should know about...
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.